Substantial weight loss typically occurs between three and six months
There is no evidence to suggest optimal duration of fasting for patients, so until we have adequate evidence, we will continue with current ASA fasting guidelines
TLDR: "Discontinuation of GLP-1RA treatment leads to weight regain, regardless of lifestyle interventions, and should therefore be considered a chronic therapy to prevent weight regain and associated undesirable outcomes related to obesity." Key findings: After stopping liraglutide, patients regained ~2.2 kg After stopping semaglutide/tirzepatide, patients regained ~9.7 kg Weight regain was proportional to initial weight loss Lifestyle changes alone DID NOT prevent regain Implication: GLP-1 receptor agonists are not a short-term solution
Potential anxiolytic and antidepressant-like effects of luteolin in a chronic constriction injury rat model of neuropathic pain: Role of oxidative stress, neurotrophins, and inflammatory factors
How PlexusDx Supports a More Personalized Approach PlexusDx Precision Peptide Genetic Test may help provide context about your individual predispositions in GLP-1 receptor signaling, appetite regulation, and metabolic rate control
